Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC‐202 blocks oncogenic hedgehog‐GLI signaling and overcomes smoothened inhibitor resistance
Wolfgang Gruber, Elisabeth Peer, Dominik P. Elmer, et al.
International Journal of Cancer (2017) Vol. 142, Iss. 5, pp. 968-975
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Non-canonical Hedgehog Signaling Pathway in Cancer: Activation of GLI Transcription Factors Beyond Smoothened
Silvia Pietrobono, Sinforosa Gagliardi, Barbara Stecca
Frontiers in Genetics (2019) Vol. 10
Open Access | Times Cited: 259
The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer?
Priyanka Bhateja, Mathew Cherian, Sarmila Majumder, et al.
Cancers (2019) Vol. 11, Iss. 8, pp. 1126-1126
Open Access | Times Cited: 120
Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer
Srinivas Patnaik, S Anupriya
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 96
Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers
Masaru Katoh
Clinical Science (2019) Vol. 133, Iss. 8, pp. 953-970
Closed Access | Times Cited: 91
Next-Generation Hedgehog/GLI Pathway Inhibitors for Cancer Therapy
Elisabeth Peer, Suzana Tesanovic, Fritz Aberger
Cancers (2019) Vol. 11, Iss. 4, pp. 538-538
Open Access | Times Cited: 86
Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective
Diamantis I. Tsilimigras, Ioannis Ntanasis‐Stathopoulos, Demetrios Moris, et al.
Surgical Oncology (2018) Vol. 27, Iss. 4, pp. 611-618
Closed Access | Times Cited: 68
The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma
Ludovica Lospinoso Severini, Francesca Ghirga, Francesca Bufalieri, et al.
Expert Opinion on Therapeutic Targets (2020) Vol. 24, Iss. 11, pp. 1159-1181
Open Access | Times Cited: 51
HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
Maria Serena Roca, Tania Moccia, Federica Iannelli, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 31
Phenformin Inhibits Hedgehog-Dependent Tumor Growth through a Complex I-Independent Redox/Corepressor Module
Laura Di Magno, Simona Manni, Fiorella Di Pastena, et al.
Cell Reports (2020) Vol. 30, Iss. 6, pp. 1735-1752.e7
Open Access | Times Cited: 47
Targeting GLI1 and GLI2 with small molecule inhibitors to suppress GLI-dependent transcription and tumor growth
Luisa Maresca, Enrica Crivaro, Francesca Migliorini, et al.
Pharmacological Research (2023) Vol. 195, pp. 106858-106858
Open Access | Times Cited: 16
Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors
Silvia Pietrobono, Barbara Stecca
Cells (2018) Vol. 7, Iss. 12, pp. 272-272
Open Access | Times Cited: 41
Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells
Marion Wobser, Alexandra Weber, Amelie Glunz, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 39
Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors
Maria Serena Roca, Elena Di Gennaro, Alfredo Budillon
Journal of Clinical Medicine (2019) Vol. 8, Iss. 7, pp. 912-912
Open Access | Times Cited: 37
Hedgehog pathway orchestrates the interplay of histone modifications and tailors combination epigenetic therapies in breast cancer
Xiaomin Wang, Jun Xu, Yiming Sun, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2601-2612
Open Access | Times Cited: 11
Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma
Hung Q. Doan, Leon Chen, Zeena Y. Nawas, et al.
Oncotarget (2021) Vol. 12, Iss. 20, pp. 2089-2100
Open Access | Times Cited: 26
Epigenetic marvels: exploring the landscape of colorectal cancer treatment through cutting-edge epigenetic-based drug strategies
Azar Tahghighi, Effat Seyedhashemi, Javad Mohammadi, et al.
Clinical Epigenetics (2025) Vol. 17, Iss. 1
Open Access
Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer
Jun Zhao, Steven G. Gray, Catherine M. Greene, et al.
Expert Review of Gastroenterology & Hepatology (2019) Vol. 13, Iss. 3, pp. 247-256
Closed Access | Times Cited: 29
Synergistic cross‐talk of hedgehog and interleukin‐6 signaling drives growth of basal cell carcinoma
Christina Sternberg, Wolfgang Gruber, Markus Eberl, et al.
International Journal of Cancer (2018) Vol. 143, Iss. 11, pp. 2943-2954
Open Access | Times Cited: 28
Inhibiting Hedgehog: An Update on Pharmacological Compounds and Targeting Strategies
Ilya Galperin, Lukas Dempwolff, Wibke E. Diederich, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 18, pp. 8392-8411
Closed Access | Times Cited: 27
Analysis of Dual Class I Histone Deacetylase and Lysine Demethylase Inhibitor Domatinostat (4SC-202) on Growth and Cellular and Genomic Landscape of Atypical Teratoid/Rhabdoid
Mariah Hoffman, Jessica L.S. Zylla, Somshuvra Bhattacharya, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 756-756
Open Access | Times Cited: 27
KCTD15 inhibits the Hedgehog pathway in Medulloblastoma cells by increasing protein levels of the oncosuppressor KCASH2
Eleonora Spiombi, Annapaola Angrisani, Simone Fonte, et al.
Oncogenesis (2019) Vol. 8, Iss. 11
Open Access | Times Cited: 23
Targeting the GLI family of transcription factors for the development of anti-cancer drugs
Christopher O. Dusek, M. Kyle Hadden
Expert Opinion on Drug Discovery (2020) Vol. 16, Iss. 3, pp. 289-302
Closed Access | Times Cited: 19
Investigation of the effect of belinostat on MCF-7 breast cancer stem cells via the Wnt, Notch, and Hedgehog signaling pathway
Zeliha Tuncer, Ercan Kurar, Tuğçe Duran
Saudi Medical Journal (2024) Vol. 45, Iss. 2, pp. 121-127
Open Access | Times Cited: 2
Novel Histone Deacetylase (HDAC) Inhibitor Induces Apoptosis and Suppresses Invasion via E-Cadherin Upregulation in Pancreatic Ductal Adenocarcinoma (PDAC)
Katja Schiedlauske, Alina Deipenbrock, Marc Pflieger, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 6, pp. 752-752
Open Access | Times Cited: 2
SIN3B Loss Heats up Cold Tumor Microenvironment to Boost Immunotherapy in Pancreatic Cancer
Zhengyan Zhang, Yingying Tang, Yu Wang, et al.
Advanced Science (2024)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top